Metraipolis › archive › dc_50001612fccf

Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted… — Europe PMC PMID:40940902

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40940902
DOI
10.3390/cancers17172805
License (as archived)
solo-consultazione
Archived
2026-11-10T08:06:47.530Z
SHA-256 of the archived text
de3896579a5a6d10379cdc48508e02b318a1906c706ab1cac380797114716975
Stable URL of this page
https://metraipolis.com/documento/dc_50001612fccf

How to cite

Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted… — Europe PMC PMID:40940902 — Europe PMC (en), https://europepmc.org/article/MED/40940902 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_50001612fccf (Metraipolis archive dc_50001612fccf, sha256 de3896579a5a6d10379cdc48508e02b318a1906c706ab1cac380797114716975)
BibTeX
@misc{dc50001612fccf,
  title = {Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted… — Europe PMC PMID:40940902},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40940902},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_50001612fccf; sha256 de3896579a5a6d10379cdc48508e02b318a1906c706ab1cac380797114716975},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40940902. Agents can read the archived copy with the MCP tool read_document.